RASolve 301

About this trial

Daxonrasib is a new investigational drug known as a RAS inhibitor. RAS stands for Rat Sarcoma Virus and is found in approx 30% of NSCLC. RAS is a group of proteins which are involved in cell growth and cell death. Mutations or changes in the RAS gene is found in some types of cancer, such as NSCLC, and can cause cancer cells to grow and spread in the body. Daxonrasib blocks mutations (changes) which can be big contributers to NSCLC.
Docetaxel is a currently established treament for NSCLC patients which is used when their initial treatment does not work. It is known as a taxane which is a type of chemotherapy drug that blocks cell growth.
The purpose of this study is to:
This study’s aim is to comparethe efficacy and safety of RMC-6236 vs Docetaxel on NSCLC.
Patients who are eligible to participate on this study will be assigned by chance (one chance in two) to one of two treatment groups via a process called randomization. Patients will recieve either RMC-6236 or Docetaxel as long as you can tolerate the treatment, until your cancer worses, until you or your doctor decides to stop the treatment or until the study is stopped.

Patient Profile

RAS-mutant NSCLC

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Galway, and Mater Private Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	RASolve 301
Number:	24-105
Full Title:	Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (RASolve 301)

Principal Investigator:	Prof Jarushka Naidoo
Type:	Industry Sponsored
Sponsor:	Revolution Medicines, Inc.
Recruitment Started:	Global: Aug 2025 Ireland: Oct 2025

Global Recruitment Target:
Ireland Recruitment Target:	13